An additional 8 therapeutic molecules were also screened in the miniaturized TPCS system in a second drug screen (Supplemental Figures S4F–H, Supplemental Digital Content 1, http://links.lww.com/HC9/B979), identifying the multi-kinase inhibitor Rigosertib and a PFKFB3 inhibitor as promising anti-HCC candidate drugs. Here, PFKFB3 is linked to hepatocellular carcinoma.